October Issue of Patient Care Online Supplement is Now Live

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

News

Article

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Patient Care Online October 2024 Supplement

The latest issue of the Patient Care Online digital supplement is now live. The October issue offers highlights of 2 expert discussions on the challenges primary care clinicians face in effectively and safely treating older adults with type 2 diabetes. A third feature summarizes an expert panel discussion on screening high risk populations for type 1 diabetes, understanding autoantibodies and staging the disease, and a novel one-time infusion that significantly delays the progression from stage II type 1 diabetes to stage III, insulin-dependent type 1 diabetes.

Find out more in the supplement, here.

Related Content

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

November 21st 2024

Obesity & Type 2 Diabetes: An Expert Discussion

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

June 30th 2023

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

November 18th 2024

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

July 22nd 2022

Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

November 11th 2024

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

November 7th 2024

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Related Content

November 21st 2024

Obesity & Type 2 Diabetes: An Expert Discussion

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

June 30th 2023

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

November 18th 2024

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

July 22nd 2022

Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

November 11th 2024

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

November 7th 2024